Last reviewed · How we verify
NCT04337593
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
Status unknown
Phase 2
Last updated 7 April 2020
What this trial tests
Phase 2 trial testing Basiliximab in Extranodal NK/T-cell Lymphoma in 20 participants. Status unknown.
Timeline
1 June 2020
Primary endpoint
31 May 2022
31 May 2022
31 December 2022
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 June 2020 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 December 2022 |
Drugs / interventions tested
- Basiliximab (BASILIXIMAB) — full drug profile →
- Pegaspargase — full drug profile →
Conditions studied
- Extranodal NK/T-cell Lymphoma — all drugs for Extranodal NK/T-cell Lymphoma →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 18 to 75, any sex, with Extranodal NK/T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Novel targeted therapies of T cell lymphomas.
Iżykowska K, Rassek K, Korsak D, Przybylski GK, et al · · 2020 · cited 49× · PMID 33384022 · DOI 10.1186/s13045-020-01006-w -
Treatment of extranodal NK/T-cell lymphoma: From past to future.
Yan Z, Yao S, Wang Z, Zhou W, et al · · 2023 · cited 22× · PMID 36825002 · DOI 10.3389/fimmu.2023.1088685 -
Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP, Cao Y, Cai J, Zhang YC, et al · · 2023 · cited 19× · PMID 37480137 · DOI 10.1186/s13045-023-01483-9 -
Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L, Chen N, Dai L, Peng X. · · 2023 · cited 12× · PMID 38026157 · DOI 10.1016/j.isci.2023.108192 -
Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.
Pichler AS, Amador C, Fujimoto A, Takeuchi K, et al · · 2025 · cited 3× · PMID 39679758 · DOI 10.1111/his.15376 -
Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies.
Zhang Q, Wang X. · · 2026 · PMID 42122154 · DOI 10.3390/cancers18091358
Verify or expand the search:
- PubMed search for NCT04337593
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Basiliximab
Trials testing the same drug.
- NCT06480630 — Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Sch · Phase 2 · not yet recruiting
- NCT05385432 — Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies · Phase 3 · not yet recruiting
- NCT06066840 — Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement · Phase 4 · unknown
- NCT05139004 — 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of H · Phase 1 · active not recruiting
- NCT04871607 — Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Prima · Phase 2 · recruiting
Other recruiting trials for Extranodal NK/T-cell Lymphoma
Currently open trials in the same condition.
- NCT06824883 — Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma · Phase 2 · recruiting
- NCT05377827 — Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU- · Phase 1 · active not recruiting
- NCT04414163 — A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type · Phase 2 · active not recruiting
- NCT06406556 — Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL · Phase 2 · recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04337593 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 7 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04337593.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing